2021 was a strong year for CRISPR gene editing, with the first in vivo data released by Intellia Therapeutics,...
From People To Planet: The Endless Potential Of CRISPR Gene Editing
Caszyme CEO and 2022 Rising Leader Monika Paule is on a mission to expand the CRISPR toolbox of available proteins to enhance diagnostic tools, therapeutics and even agricultural practices.
More from Leadership
More from In Vivo
• By
Entrepreneurialism is in the blood of Israel’s medtech innovators, but in a changing medtech world, the local ecosystem must address funding gaps and manufacturing and infrastructure needs. So says Ruti Alon, experienced Israeli medtech leader, investor and co-chair of the Biomed Israel conference.
• By
During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.
• By
Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.